2026 CPT® Updates

AAPC

Copyright © 2024 AAPC

1

CPT® Disclaimer

- CPT® copyright 2025 American Medical Association. All rights reserved.
- Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT® and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
- CPT® is a registered trademark of the American Medical Association.

2

Objectives

- Overview of the new, revised, and deleted CPT® codes for 2026
- Review documentation requirements for the new codes

3

Code Changes — Now What?

- Review 2026 CPT® code changes.
- Order 2026 code books.
- Review all changes to guidelines, notes, and instructions in your book.
- Highlight changes in the book's index pertinent to your specialty and review those changes.

4

Code Changes — Now What?

- Highlight changes in the tabular section pertinent to your specialty.
- Create a “cheat sheet” of 2026 updates that must be documented differently to capture the needed information and distribute it to clinicians.
- Review and update superbills, chargemasters, etc.

5

Code Changes — Now What?

- Upload software changes.
- Train coding and billing staff on changes.
- Check for addenda or errata.
- Communicate with payer/provider reps regarding reimbursement and coverage issues.
- Archive last year’s books.

6

Unchanged for 2026

- Appendices
- Anesthesia codes
- CPT® modifiers

7

Evaluation and Management

#▲ **99453**	**Remote monitoring of physiologic parameter(s)** (eg, weight, blood pressure, pulse oximetry, respiratory flow rate)~~,~~: initial~~,~~ set-up and patient education on use of equipment
#● **99445**	device(s) supply with daily recording(s) or programmed alert(s) transmission, 2-15 days in a 30-day period
#▲ **99454**	device(s) supply with daily recording(s) or programmed alert(s) transmission, 16-30 days in a 30-day period~~each 30 days~~
#● **99470**	**Remote physiologic monitoring treatment management services,** clinical staff/physician/other qualified health care professional time in a calendar month requiring 1 real-time interactive communication with the patient/caregiver during the calendar month; first 10 minutes
#▲ **99457**	~~**Remote physiologic monitoring treatment management services,** clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month;~~ first 20 minutes
#**+**▲ **99458**	~~**Remote physiologic monitoring treatment management services,** clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month;~~ each additional 20 minutes (List separately in addition to code for primary procedure)

8

Surgery

▲ **10040** Extraction~~Acne surgery~~ (eg, marsupialization, opening or removal of multiple milia, comedones, cysts, pustules)

9

Surgery

▲ **27278** Arthrodesis, sacroiliac joint, percutaneous~~,~~ or minimally invasive, with image guidance, ~~including~~includes obtaining bone graft when performed, unilateral ~~placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device~~; placement of intra-articular device(s), without cortical piercing

▲ **27279** ~~Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, includes obtaining bone graft when performed, and placement of transfixation device~~; placement of transarticular device(s) and/or intra-articular device(s) piercing the lateral or medial cortices of the ilium and the lateral cortex of the sacrum

~~**27445** Arthroplasty, knee, hinge prosthesis (eg, Walldius type)~~

#● **27458** Osteotomy(ies), femur, unilateral, with insertion of an externally controlled intramedullary lengthening device, including iliotibial band release when performed, imaging, alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device

~~**27468** combined, lengthening and shortening with femoral segment transfer~~

● **27713** Osteotomy(ies), tibia, including fibula when performed, unilateral, with insertion of an externally controlled intramedullary lengthening device, including imaging, alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device

10

Surgery

▲ **33880** Endovascular repair of ~~descending~~ thoracic aorta, including pre-procedure sizing and device selection, nonselective catheterization(s), all associated radiological supervision and interpretation ~~(eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); involving coverage of left subclavian artery origin, initial endoprosthesis plus descending thoracic aortic extension(s), if required, to level of celiac artery origin~~by deployment of an aorto-aortic tube endograft covering the left subclavian artery and all aortic tube endograft extension(s) proximally in the aortic arch and ascending aorta and distally to the celiac artery, when performed

▲ **33881** ~~not involving coverage of left subclavian artery origin, initial endoprosthesis plus descending thoracic aortic extension(s), if required, to level of celiac artery origin~~by deployment of an aorto-aortic tube endograft not involving coverage of the left subclavian artery origin and all endograft extension(s) placed from the level of the left subclavian carotid artery to the celiac artery

● **33882** Endovascular repair of the thoracic aorta by deployment of a branched endograft multipiece system involving an aorto-aortic tube device with a fenestration for the left subclavian artery stent graft(s) and all aortic tube endograft extension(s) placed from the level of the left common carotid artery to the celiac artery, including pre-procedure sizing and device selection, all target zone angioplasty, all nonselective catheterization(s) and left subclavian artery selective catheterization(s), and all associated radiological supervision and interpretation

11

Surgery

▲ **33883** Delayed placement of proximal extension prosthesis(es) not involving coverage of the left subclavian artery origin, after endovascular repair of the thoracic aorta, including pre-procedure sizing and device selection, nonselective catheterization(s), all associated radiological supervision and interpretation, and treatment zone angioplasty/stenting, when performed~~Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); initial extension~~

~~33884~~ ~~Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); each additional proximal extension (List separately in addition to code for primary procedure)~~

▲ **33886** Delayed placement of distal extension prosthesis(es) from the level of the left subclavian artery to the celiac artery, after endovascular repair of descending thoracic aorta, including pre-procedure sizing and device selection, all nonselective catheterization(s), all associated radiological supervision and interpretation~~Placement of distal extension prosthesis(s) delayed after endovascular repair of descending thoracic aorta~~

~~33889~~ ~~Open subclavian to carotid artery transposition performed in conjunction with endovascular repair of descending thoracic aorta, by neck incision, unilateral~~

12

Surgery

~~**33891**~~ ~~Bypass graft, with other than vein, transcervical retropharyngeal carotid-carotid, performed in conjunction with endovascular repair of descending thoracic aorta, by neck incision~~

- **35602** carotid-contralateral carotid

~~**37220**~~ ~~Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal angioplasty~~

~~**37221**~~ ~~with transluminal stent placement(s), includes angioplasty within the same vessel, when performed~~

~~**37222**~~ ~~Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)~~

~~**37223**~~ ~~with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)~~

~~**37224**~~ ~~Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty~~

13

Surgery

~~**37225**~~ ~~with atherectomy, includes angioplasty within the same vessel, when performed~~

~~**37226**~~ ~~with transluminal stent placement(s), includes angioplasty within the same vessel, when performed~~

~~**37227**~~ ~~with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed~~

~~**37228**~~ ~~Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty~~

~~**37229**~~ ~~with atherectomy, includes angioplasty within the same vessel, when performed~~

~~**37230**~~ ~~with transluminal stent placement(s), includes angioplasty within the same vessel, when performed~~

~~**37231**~~ ~~with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed~~

14

Surgery

~~**37232** Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)~~

~~**37233** with atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)~~

~~**37234** with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)~~

~~**37235** with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)~~

15

Surgery

#● **37254** Revascularization, endovascular, open or percutaneous, iliac vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; straightforward lesion, initial vessel

#+● **37255** straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)

#● **37256** Revascularization, endovascular, open or percutaneous, iliac vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; complex lesion, initial vessel

#+● **37257** complex lesion, each additional vessel (List separately in addition to code for primary procedure)

16

Surgery

#●	**37258**	Revascularization, endovascular, open or percutaneous, iliac vascular territory, with transluminal stent placement, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37259**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37260**	Revascularization, endovascular, open or percutaneous, iliac vascular territory, with transluminal stent placement, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37261**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)
#+●	**37262**	Intravascular lithotripsy(ies), iliac vascular territory, including all imaging guidance and radiological supervision and interpretation necessary to perform the intravascular lithotripsy(ies) within the same artery (List separately in addition to code for primary procedure)

17

Surgery

#●	**37263**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37264**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37265**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; complex lesion, initial vessel
#+●	**37266**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

18

Surgery

#●	**37267**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal stent placement, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37268**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37269**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal stent placement, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37270**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

19

Surgery

#●	**37271**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the atherectomy and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37272**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37273**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the atherectomy and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37274**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

20

Surgery

#●	**37275**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal stent placement, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement, atherectomy, and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37276**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37277**	Revascularization, endovascular, open or percutaneous, femoral and popliteal vascular territory, with transluminal stent placement, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement, atherectomy, and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37278**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)
#+●	**37279**	Intravascular lithotripsy(ies), femoral and popliteal vascular territory, including all imaging guidance and radiological supervision and interpretation necessary to perform the intravascular lithotripsy(ies) within the same artery (List separately in addition to code for primary procedure)

21

Surgery

#●	**37280**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37281**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37282**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; complex lesion, initial vessel
#+●	**37283**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

22

Surgery

#●	**37284**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal stent placement, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37285**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37286**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal stent placement, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37287**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

23

Surgery

#●	**37288**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the atherectomy and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37289**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37290**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the atherectomy and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37291**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

24

Surgery

#●	**37292**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal stent placement, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement, atherectomy, and angioplasty when performed, within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37293**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37294**	Revascularization, endovascular, open or percutaneous, tibial and peroneal vascular territory, with transluminal stent placement, with transluminal atherectomy, including transluminal angioplasty when performed, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the stent placement, atherectomy, and angioplasty when performed, within the same artery, unilateral; complex lesion, initial vessel
#+●	**37295**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)

25

Surgery

#●	**37296**	Revascularization, endovascular, open or percutaneous, inframalleolar vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; straightforward lesion, initial vessel
#+●	**37297**	straightforward lesion, each additional vessel (List separately in addition to code for primary procedure)
#●	**37298**	Revascularization, endovascular, open or percutaneous, inframalleolar vascular territory, with transluminal angioplasty, including all maneuvers necessary for accessing and selectively catheterizing the artery and crossing the lesion, including all imaging guidance and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, unilateral; complex lesion, initial vessel
#+●	**37299**	complex lesion, each additional vessel (List separately in addition to code for primary procedure)
	~~**37500**~~	~~Vascular endoscopy, surgical, with ligation of perforator veins, subfascial (SEPS)~~

26

Surgery

- **43889** Gastric restrictive procedure, transoral, endoscopic sleeve gastroplasty (ESG), including argon plasma coagulation, when performed
- **47384** Ablation, irreversible electroporation, liver, 1 or more tumors, including imaging guidance, percutaneous

27

Surgery

- **52443** Cystourethroscopy with initial transurethral anterior prostate commissurotomy with a nondrug-coated balloon catheter followed by therapeutic drug delivery into the prostate by a drug-coated balloon catheter, including transrectal ultrasound and fluoroscopy, when performed
- **52597** Transurethral robotic-assisted waterjet resection of prostate, including intraoperative planning, ultrasound guidance, control of postoperative bleeding, complete, including vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy, when performed

~~**52647** Laser coagulation of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included if performed)~~

~~**55700** Biopsy, prostate; needle or punch, single or multiple, any approach~~

▲ **55705** Biopsy, prostate, any approach, nonimaging-guided; ~~incisional, any approach~~

28

Surgery

#●	**55707**	Biopsy, prostate, transrectal, ultrasound-guided (ie, sextant, ultrasound-localized discrete lesion[s])
#●	**55708**	Biopsy, prostate, transrectal, ultrasound-guided (ie, sextant) with MRI-fusion-guidance, first targeted lesion
#●	**55709**	Biopsy, prostate, transperineal, ultrasound-guided (ie, sextant, ultrasound-localized discrete lesion[s])
#●	**55710**	Biopsy, prostate, transperineal, ultrasound-guided (ie, sextant) with MRI-fusion-guidance biopsy, first targeted lesion
#●	**55711**	Biopsy, prostate, transrectal, MRI-ultrasound-fusion guided, targeted lesion(s) only, first targeted lesion
#●	**55712**	Biopsy, prostate, transperineal, MRI-ultrasound-fusion guided, targeted lesion(s) only, first targeted lesion
#●	**55713**	Biopsy, prostate, in-bore CT- or MRI-guided (ie, sextant), with biopsy of additional targeted lesion(s), first targeted lesion

29

Surgery

#●	**55714**	Biopsy, prostate, in-bore CT- or MRI-guided targeted lesion(s) only, first targeted lesion
#✚●	**55715**	Biopsy, prostate, each additional, MRI-ultrasound fusion or in-bore CT- or MRI-guided targeted lesion (List separately in addition to code for primary procedure)
▲	**55866**	Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed;
#●	**55868**	with lymph node biopsy(ies) (limited pelvic lymphadenectomy)
#●	**55869**	with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes
#●	**55877**	Ablation, irreversible electroporation, prostate, 1 or more tumors, including imaging guidance, percutaneous

30

Surgery

▲ **61624**	Transcatheter permanent occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), including all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention, percutaneous, any method; central nervous system (intracranial, spinal cord)
▲ **61626**	non-central nervous system, head or neck (extracranial, brachiocephalic branch)
#▲ **62287**	Decompression ~~procedure~~, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle–based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar
● **62330**	Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, CT or fluoroscopy), bilateral; one interspace, lumbar
+● **62331**	additional interspace(s), lumbar (List separately in addition to code for primary procedure)
+● **63032**	with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure)

31

Surgery

● **64567**	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation
#● **64654**	Initial open implantation of baroreflex activation therapy (BAT) modulation system, including lead placement onto the carotid sinus, lead tunnelling, connection to a pulse generator placed in a distant subcutaneous pocket (ie, total system), and intraoperative interrogation and programming
#● **64655**	Revision or replacement of baroreflex activation therapy (BAT) modulation system, with intraoperative interrogation and programming; lead only
#● **64656**	pulse generator only
#● **64657**	Removal of baroreflex activation therapy (BAT) modulation system; total system, including lead and pulse generator
#● **64658**	lead only
#● **64659**	pulse generator only
#● **64728**	median nerve at the carpal tunnel, percutaneous, with intracarpal tunnel balloon dilation, including ultrasound guidance

32

Radiology

- **70471** Computed tomographic angiography (CTA), head and neck, with contrast material(s), including noncontrast images, when performed, and image postprocessing

+ • **70472** Computed tomographic (CT) cerebral perfusion analysis with contrast material(s), including image postprocessing performed with concurrent CT or CT angiography of the same anatomy (List separately in addition to code for primary procedure)

- **70473** Computed tomographic (CT) cerebral perfusion analysis with contrast material(s), including image postprocessing performed without concurrent CT or CT angiography of the same anatomy
- **75577** Quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, derived from augmentative software analysis of the data set from a coronary computed tomographic angiography, with interpretation and report by a physician or other qualified health care professional

33

Radiology

~~**75842** Venography, adrenal, bilateral, selective, radiological supervision and interpretation~~

~~**75956** Endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption); involving coverage of left subclavian artery origin, initial endoprosthesis plus descending thoracic aortic extension(s), if required, to level of celiac artery origin, radiological supervision and interpretation~~

~~**75957** not involving coverage of left subclavian artery origin, initial endoprosthesis plus descending thoracic aortic extension(s), if required, to level of celiac artery origin, radiological supervision and interpretation~~

~~**75958** Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (eg, aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption), radiological supervision and interpretation~~

~~**75959** Placement of distal extension prosthesis(s) (delayed) after endovascular repair of descending thoracic aorta, as needed, to level of celiac origin, radiological supervision and interpretation~~

34

Radiology

~~77014~~ ~~Computed tomography guidance for placement of radiation therapy fields~~

~~77401~~ ~~Radiation treatment delivery, superficial and/or ortho voltage, per day~~

▲ **77402** Radiation treatment delivery~~, ≥1 MeV~~; Level 1 ~~simple~~(eg, single-electron field, multiple-electron fields, or 2D photons), including imaging guidance, when performed

▲ **77407** Level 2~~intermediate~~, single-isocenter (eg, 3D or IMRT), photons, including imaging guidance, when performed

▲ **77412** Level 3~~complex~~, multiple isocenters with photon therapy (eg, 2D, 3D, or IMRT) **or** a single-isocenter photon therapy (eg, 3D or IMRT) with active motion management, **or** total skin electrons, **or** mixed-electron/photon field(s), including imaging guidance, when performed

35

Radiology

~~77385~~ ~~Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple~~

~~77386~~ ~~complex~~

#● **77436** Surface radiation therapy; superficial or orthovoltage, treatment planning and simulation-aided field setting

#● **77437** superficial, delivery, ≤150 kV, per fraction (eg, electronic brachytherapy)

#● **77438** orthovoltage, delivery, >150-500 kV, per fraction

#✚● **77439** superficial or orthovoltage, image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous tumors, per course of treatment (List separately in addition to code for primary procedure)

36

Pathology and Laboratory

#●	**81354**	interrogation of structural and copy number variants, optical genome mapping (OGM)
●	**81524**	Oncology (central nervous system tumor), DNA methylation analysis of at least 10,000 methylation sites, utilizing DNA extracted from formalin-fixed tumor tissue, algorithm(s) reported as probability of matching a reference tumor family and class, and *MGMT (O-6-methylguanine-DNA methyltransferase)* promoter methylation status, if performed
▲	**83015**	Heavy metal (eg, antimony, arsenic, barium, beryllium, bismuth, ~~antimony~~gadolinium, mercury); qualitative, any number of analytes
▲	**83018**	quantitative, each, not elsewhere specified
●	**87182**	carbapenemase enzyme detection (eg, Klebsiella pneumoniae carbapenemase [KPC], New Delhi metallo-beta-lactamase [NDM], Verona integron-encoded metallo-beta-lactamase [VIM]), multiplex immunoassay, qualitative, per isolate
●	**87183**	carbapenem resistance genes (eg, *bla*$_{KPC}$, *bla*$_{NDM}$, *bla*$_{VIM}$, *bla*$_{OXA-48}$, *bla*$_{IMP}$), amplified probe technique, per isolate
#●	**87494**	Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique
#●	**87627**	joint space pathogens and drug resistance genes, multiplex amplified probe technique, 26 or more targets
#●	**87812**	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B

37

Pathology and Laboratory

	~~**0033U**~~	~~HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.759C>T] and rs1414334 [c.551-3008C>G])~~
▲	**0095U**	Eosinophilic esophagitis, 2 protein biomarkers (Eotaxin-3 *[CCL26 {C-C motif chemokine ligand 26}]* and ~~m~~Major ~~b~~Basic ~~p~~Protein *[PRG2 {proteoglycan 2, pro eosinophil major basic protein}]*), enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis
	~~**0131U**~~	~~Hereditary breast cancerrelated disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)~~
	~~**0132U**~~	~~Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)~~
	~~**0135U**~~	~~Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)~~

38

Pathology and Laboratory

~~**0240U**~~ ~~Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected~~

~~**0241U**~~ ~~Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected~~

▲ **0285U** Oncology, disease progression and response monitoring to radiation, chemotherapy, or other systematic cancer treatments, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported in~~as~~ ng/mL~~a radiation toxicity score~~

~~**0346U**~~ ~~Beta amyloid, Aβ40 and Aβ42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma~~

~~**0361U**~~ ~~Neurofilament light chain, digital immunoassay, plasma, quantitative~~

39

Pathology and Laboratory

▲ **0365U** Oncology (bladder), ~~analysis of~~ 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm, including patient's age, race, and gender, reported as a probability of harboring urothelial~~bladder~~ cancer

~~**0369U**~~ ~~Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique~~

~~**0370U**~~ ~~Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab~~

~~**0373U**~~ ~~Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen~~

~~**0374U**~~ ~~Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine~~

~~**0380U**~~ ~~Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and *CYP2D6* deletion or duplication analysis with reported genotype and phenotype~~

40

Pathology and Laboratory

~~0428U~~ ~~Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden~~

~~0448U~~ ~~Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions in *EGFR* and *KRAS* genes, formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options~~

~~0450U~~ ~~Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides~~

~~0451U~~ ~~Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance~~

41

Pathology and Laboratory

~~0456U~~ ~~Autoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anti-cyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy~~

~~0508U~~ ~~Transplantation medicine, quantification of donorderived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection~~

~~0509U~~ ~~Transplantation medicine, quantification of donorderived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection~~

- **0521U** Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood
- **0522U** Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiqualitative, blood

42

Pathology and Laboratory

- **0523U** Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change
- **0524U** Obstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value
- **0525U** Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug
- **0526U** Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time

43

Pathology and Laboratory

- **0527U** Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected
- **0528U** Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria
- **0529U** Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including *F2* and *F5* gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE
- **0530U** Oncology (pan-solid tumor), ctDNA, utilizing plasma, next-generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy-number alterations, with therapy association
- **0531U** Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma

44

Pathology and Laboratory

- **0532U** Rare diseases (constitutional disease/hereditary disorders), rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, peripheral blood, buffy coat, saliva, buccal or tissue sample, results reported as positive or negative
- **0533U** Drug metabolism (adverse drug reactions and drug response), genotyping of 16 genes (ie, *ABCG2, CYP2B6, CYP2C9, CYP2C19, CYP2C, CYP2D6, CYP3A5, CYP4F2, DPYD, G6PD, GGCX, NUDT15, SLCO1B1, TPMT, UGT1A1, VKORC1),* reported as metabolizer status and transporter function
- **0534U** Oncology (prostate), microRNA, single-nucleotide polymorphisms (SNPs) analysis by RT-PCR of 32 variants, using buccal swab, algorithm reported as a risk score
- **0535U** Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative
- **0536U** Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of *RHD* gene and housekeeping control gene *GAPDH* from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status

45

Pathology and Laboratory

- **0537U** Oncology (colorectal cancer), analysis of cell-free DNA for epigenomic patterns, next-generation sequencing, >2,500 differentially methylated regions (DMRs), plasma, algorithm reported as positive or negative
- **0538U** Oncology (solid tumor), next-generation targeted sequencing analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant
- **0539U** Oncology (solid tumor), cell-free circulating tumor DNA (ctDNA), 152 genes, next-generation sequencing, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, copy number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant
- **0540U** Transplantation medicine, quantification of donor-derived cell-free DNA using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free DNA to determine probability of rejection

46

Pathology and Laboratory

- **0541U** Cardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score
- **0542U** Nephrology (renal transplant), urine, nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of BK virus (human polyomavirus 1) using real-time PCR and serum creatinine, algorithm reported as a probability score for allograft injury status
- **0543U** Oncology (solid tumor), next-generation sequencing of DNA from formalin-fixed paraffin-embedded (FFPE) tissue of 517 genes, interrogation for single-nucleotide variants, multi-nucleotide variants, insertions and deletions from DNA, fusions in 24 genes and splice variants in 1 gene from RNA, and tumor mutation burden

~~**0544U** Nephrology (transplant monitoring), 48 variants by digital PCR, using cell-free DNA from plasma, donor-derived cell-free DNA, percentage reported as risk for rejection~~

47

Pathology and Laboratory

- **0545U** Acetylcholine receptor (AChR), antibody identification by immunofluorescence, using live cells, reported as positive or negative
- **0546U** Low-density lipoprotein receptor-related protein 4 (LRP4), antibody identification by immunofluorescence, using live cells, reported as positive or negative
- **0547U** Neurofilament light chain (NfL), chemiluminescent enzyme immunoassay, plasma, quantitative
- **0548U** Glial fibrillary acidic protein (GFAP), chemiluminescent enzyme immunoassay, using plasma
- **0549U** Oncology (urothelial), DNA, quantitative methylated real-time PCR of TRNA-Cys, SIM2, and NKX1-1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (UTUC)

~~**0550U** Oncology (prostate), enzyme-linked immunosorbent assays (ELISA) for total prostate-specific antigen (PSA) and free PSA, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer~~

48

Pathology and Laboratory

- ~~**0551U**~~ ~~Tau, phosphorylated, pTau217, by single-molecule array (ultrasensitive digital protein detection), using plasma~~
- **0552U** Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophectoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder
- **0553U** Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested
- **0554U** Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from trophectoderm biopsy for aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested

49

Pathology and Laboratory

- **0555U** Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested
- **0556U** Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
- **0557U** Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for Atopobium vaginae, Gardnerella vaginalis, Megasphaera types 1 and 2, bacterial vaginosis associated bacteria-2 and -3 (BVAB-2, BVAB-3), Mobiluncus species, Trichomonas vaginalis, Neisseria gonorrhoeae, Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei), Herpes simplex viruses 1 and 2, vaginal fluid, reported as detected or not detected for each organism

50

Pathology and Laboratory

- **0558U** Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker (BF7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression
- **0559U** Oncology (breast), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker (BF9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression
- **0560U** Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood and tumor tissue, baseline assessment for design and construction of a personalized variant panel to evaluate current MRD and for comparison to subsequent MRD assessments
- **0561U** Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood, subsequent assessment with comparison to initial assessment to evaluate for MRD

51

Pathology and Laboratory

- **0562U** Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (SNVs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free DNA, plasma, reported as presence of actionable variants
- **0563U** Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative
- **0564U** Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative
- **0565U** Oncology (hepatocellular carcinoma), next-generation sequencing methylation pattern assay to detect 6,626 epigenetic alterations, cell-free DNA, plasma, algorithm reported as cancer signal detected or not detected

52

Pathology and Laboratory

- **0566U** Oncology (lung), qPCR-based analysis of 13 differentially methylated regions *(CCDC181, HOXA7, LRRC8A, MARCHF11, MIR129-2, NCOR2, PANTR1, PRKCB, SLC9A3, TBR1_2, TRAP1, VWC2, ZNF781),* pleural fluid, algorithm reported as a qualitative result
- **0567U** Rare diseases (constitutional/heritable disorders), whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants
- **0568U** Neurology (dementia), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio), tau-protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology
- **0569U** Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (>20,000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate

53

Pathology and Laboratory

- **0570U** Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison
- **0571U** Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants
- **0572U** Oncology (prostate), high-throughput telomere length quantification by FISH, whole blood, diagnostic algorithm reported as risk of prostate cancer
- **0573U** Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastricsin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous
- **0574U** Mycobacterium tuberculosis, culture filtrate protein–10-kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MS)

54

Pathology and Laboratory

- **0575U** Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes *(miR-122*, *miR-885*, *miR-23a* housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection
- **0576U** Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free DNA (cfDNA) by whole genome next-generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score
- **0577U** Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode, reported as likelihood of malignancy
- **0578U** Oncology (cutaneous melanoma), RNA, gene expression profiling by real-time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence
- **0579U** Nephrology (diabetic chronic kidney disease), enzyme-linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigen-like (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline

55

Pathology and Laboratory

- **0580U** Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG
- **0581U** Transplantation medicine, antibody to non-human leukocyte antigens (non-HLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported
- **0582U** Rare diseases (constitutional disease/hereditary disorders), rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported
- ✚ **0583U** Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results (List separately in addition to code for primary procedure)
- ♓ **0584U** Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative

56

Pathology and Laboratory

- **0585U** Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability
- **0586U** Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin-fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene
- **0587U** Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects
- **0588U** Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split-well multiplex reverse transcription loop-mediated isothermal amplification (RT-LAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days

57

Pathology and Laboratory

- **0589U** Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative
- **0590U** Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism
- **0591U** Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer
- **0592U** Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor tissue, results report clinically significant variant(s)
- **0593U** Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected

58

Pathology and Laboratory

- **0594U** Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis
- **0595U** Infectious disease (tropical fever pathogens), vector-borne and zoonotic pathogens, including 2 viruses (Chikungunya virus and Dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (Leptospira species), and 1 parasite with species differentiation (Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale), real-time RT-PCR, whole blood, each pathogen reported as detected or not detected
- **0596U** Neurology (Alzheimer disease), plasma, 3 distinct isoform-specific peptides (APOE2, APOE3, and APOE4) by liquid chromatography with tandem mass spectrometry (LC-MS/MS), reported as an APOE prototype
- **0597U** Oncology (breast), RNA expression profiling of 329 genes by targeted next-generation sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic analyses to determine tumor-recurrence risk score
- **0598U** Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels

59

Pathology and Laboratory

- **0599U** Oncology (pancreatic cancer), multiplex immunoassay of ICAM1, TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm reported as positive or negative
- **0600U** Infectious disease (wound infection), identification of 65 organisms and 30 antibiotic resistance genes, wound swab, real-time PCR, reported as positive or negative for each organism
- **0601U** Infectious disease (periprosthetic joint infection), analysis of 11 biomarkers (alpha defensins 1–3, C-reactive protein, microbial antigens for Staphylococcus [SPA, SPB], Enterococcus, Candida, and C. acnes, total nucleated cell count, percent neutrophils, RBC count, and absorbance at 280 nm) using immunoassays, hematology, clinical chemistry, synovial fluid, and diagnostic algorithm reported as a probability score
- **0602U** Endocrinology (diabetes), insulin (INS) gene methylation using digital droplet PCR, insulin, and C-peptide immunoassay, serum, Hemoglobin A1c immunoassay, whole blood, algorithm reported as diabetes-risk score
- **0603U** Drug assay, presumptive, 77 drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS), results reported as positive or negative

60

Pathology and Laboratory

- **0604U** Allergy and immunology (chronic recurrent angioedema), 4 bradykinin peptides, liquid chromatography and tandem mass spectrometry (LC-MS/ MS), whole blood, quantitative
- **0605U** Allergy and immunology (hereditary alpha tryptasemia), DNA, analysis of TPSAB1 gene copy number variation using digital PCR, whole blood, results reported with genotype-specific interpretation of alpha-tryptase copy number and algorithmic classification as normal or abnormal
- **0606U** Hematology (red cell membrane disorders), RBCs, osmotic gradient ektacytometry, whole blood, quantitative
- **0607U** Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 31 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations
- **0608U** Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 10 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations

61

Pathology and Laboratory

- **0609U** Oncology (prostate), immunoassay for total prostate-specific antigen (PSA) and free PSA, serum or plasma, combined with clinical features, algorithm reported as a probability score for clinically significant prostate cancer
- **0610U** Infectious disease (antimicrobial susceptibility), phenotypic antimicrobial susceptibility testing of positive blood culture using microfluidic sensor technology to quantify bacterial growth response to multiple antibiotic types, reporting categorical susceptibility (susceptible, susceptible dose dependent, intermediate, resistant), minimum inhibitory concentration, and interpretive comments
- ♓ **0611U** Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result
- ♓ **0612U** Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result
- **0613U** Oncology (urothelial carcinoma), DNA methylation and mutation analysis of 6 biomarkers (TWIST1, OTX1, ONECUT2, FGFR3, HRAS, TERT promoter region), methylation-specific PCR and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma

62

Medicine

●	**90382**	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use
▲	**90480**	Immunization administration by intramuscular injection, ~~of~~ severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine~~, single dose~~; first or only component of each vaccine administered
+ ●	**90481**	each additional component administered (List separately in addition to code for primary procedure)
★◀ ●	**90482**	Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service; 3 minutes up to 10 minutes
★◀ ●	**90483**	greater than 10 minutes up to 20 minutes
★◀ ●	**90484**	greater than 20 minutes

63

Medicine

# ●	**91323**	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use
# ●	**90593**	Chikungunya virus vaccine, recombinant, for intramuscular use
# ϟ ●	**90631**	Influenza virus vaccine (IIV), H5, pandemic formulation, split virus, adjuvanted, for intramuscular use
# ●	**90635**	Influenza virus vaccine, H5N1, derived from cell cultures, adjuvanted, for intramuscular use
# ϟ ●	**90612**	Influenza virus vaccine, trivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 31.7 mcg/0.32 mL dosage, for intramuscular use
# ϟ ●	**90613**	Influenza virus vaccine, quadrivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 40 mcg/0.4 mL dosage, for intramuscular use

64

Medicine

#▲	**90620**	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), ~~2 dose schedule,~~ for intramuscular use
	~~**91120**~~	~~Rectal sensation, tone, and compliance test (ie, response to graded balloon distention)~~
	~~**91122**~~	~~Anorectal manometry~~
●	**91124**	Rectal sensation, tone, and compliance study (eg, barostat)
●	**91125**	Anorectal manometry, with rectal sensation and rectal balloon expulsion test, when performed
▲	**92284**	Diagnostic dark adaptation examination (eg, rod and cone sensitivities, rod-cone breakpoint), with interpretation and report
#●	**92288**	Screening dark adaptation measurement (eg, rod recovery intercept time), with interpretation and report

65

Medicine

	~~**92590**~~	~~Hearing aid examination and selection; monaural~~
	~~**92591**~~	~~binaural~~
	~~**92592**~~	~~Hearing aid check; monaural~~
	~~**92593**~~	~~binaural~~
	~~**92594**~~	~~Electroacoustic evaluation for hearing aid; monaural~~
	~~**92595**~~	~~binaural~~
●	**92628**	Evaluation for hearing aid candidacy, unilateral or bilateral, including review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, and, when performed, assessment of cognitive and communication status; first 30 minutes
+●	**92629**	each additional 15 minutes (List separately in addition to code for primary procedure)

66

Medicine

#●	**92631**	Hearing aid selection services, unilateral or bilateral, including review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report; first 30 minutes
#✚●	**92632**	each additional 15 minutes (List separately in addition to code for primary procedure)
#●	**92634**	Hearing aid fitting services, unilateral or bilateral, including device analysis, programming, verification, counseling, orientation, and training, and, when performed, hearing assistive device, supplemental technology fitting services; first 60 minutes
#✚●	**92635**	each additional 15 minutes (List separately in addition to code for primary procedure)

67

Medicine

#●	**92636**	Hearing aid post-fitting follow-up services, unilateral or bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, and, when performed, hearing assistive device, supplemental technology fitting services; first 30 minutes
#✚●	**92637**	each additional 15 minutes (List separately in addition to code for primary procedure)
#✚●	**92638**	Behavioral verification of amplification including aided thresholds, functional gain, speech-in-noise, when performed (List separately in addition to code for primary procedure)
#✚●	**92639**	Hearing-aid measurement, verification with probe-microphone (List separately in addition to code for primary procedure)
#⃠●	**92641**	Hearing device verification, electroacoustic analysis

68

Medicine

#● **92642** Hearing assistive device, supplemental technology fitting services (eg, personal frequency modulation [FM]/digital modulation [DM] system, remote microphone, alerting devices)

#▲ **92920** Percutaneous transluminal coronary angioplasty~~;~~, single major coronary artery and/or its branch(es)

~~92921~~ ~~Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)~~

#▲ **92924** Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed~~;~~, single major coronary artery and/or its branch(es)

~~92925~~ ~~Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)~~

69

Medicine

#▲ **92928** Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed~~;~~, single major coronary artery and/or its branch(es); 1 lesion involving 1 or more coronary segments

~~92929~~ ~~Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)~~

#● **92930** 2 or more distinct coronary lesions with 2 or more coronary stents deployed in 2 or more coronary segments, or a bifurcation lesion requiring angioplasty and/or stenting in both the main artery and the side branch

#▲ **92933** Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed~~;~~, single major coronary artery and/or its branch(es)

70

Medicine

	~~92934~~	~~Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)~~
#▲	**92937**	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed~~;~~, single major coronary artery and/or its branches~~vessel~~
	~~92938~~	~~Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)~~
#▲	**92941**	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, ~~coronary artery or coronary artery bypass graft,~~ any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single ~~vessel~~major coronary artery and/or its branches or single bypass graft and/or its subtended branches

71

Medicine

#▲	**92943**	Percutaneous transluminal revascularization of chronic total occlusion, single coronary artery, coronary artery branch, or coronary artery bypass graft, and/or subtended major coronary artery branches of the bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; ~~single vessel~~antegrade approach
	~~92944~~	~~Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)~~
#●	**92945**	combined antegrade and retrograde approaches
#✚▲	**92973**	Percutaneous transluminal coronary mechanical aspiration thrombectomy ~~mechanical~~ (List separately in addition to code for primary procedure)
	~~92975~~	~~Thrombolysis, coronary; by intracoronary infusion, including selective coronary angiography~~
	~~92977~~	~~by intravenous infusion~~

72

Medicine

#●	**93145**	Interrogation device evaluation (in person), carotid sinus baroreflex activation therapy (BAT) modulation system including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); without programming
#●	**93146**	with programming, including optimization of tolerated therapeutic level setting
+▲	**93571**	Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress, when performed; initial vessel (List separately in addition to code for primary procedure)
+▲	**93572**	each additional vessel (List separately in addition to code for primary procedure)
	~~**94662**~~	~~Continuous negative pressure ventilation (CNP), initiation and management~~
●	**97007**	Mechanical scalp cooling, including individual cap supply with head measurement, fitting, and patient education

73

Medicine

●	**97008**	Mechanical scalp cooling; including hair preparation, individual cap placement, therapy initiation, and precooling period
+●	**97009**	provided after discontinuation of chemotherapy, each 30 minutes (List separately in addition to code for primary procedure)
#●	**98984**	device(s) supply for data access or data transmissions to support monitoring of respiratory system, 2-15 days in a 30-day period
▲	**98976**	device(s) supply for data access or data transmissions to support monitoring of respiratory system, ~~each 30 days~~16-30 days in a 30-day period
#●	**98985**	device(s) supply for data access or data transmissions to support monitoring of musculoskeletal system, 2-15 days in a 30-day period
▲	**98977**	device(s) supply for data access or data transmissions to support monitoring of musculoskeletal system, ~~each 30 days~~16-30 days in a 30-day period
#●	**98986**	device(s) supply for data access or data transmissions to support monitoring of cognitive behavioral therapy, 2-15 days in a 30-day period
▲	**98978**	device(s) supply for data access or data transmissions to support monitoring of cognitive behavioral therapy, ~~each 30 days~~16-30 days in a 30-day period

74

Medicine

●	**98979**	Remote therapeutic monitoring treatment management services, physician or other qualified health care professional time in a calendar month requiring at least 1 real-time interactive communication with the patient or caregiver during the calendar month; first 10 minutes
▲	**98980**	~~Remote therapeutic monitoring treatment management services, physician or other qualified health care professional time in a calendar month requiring at least one interactive communication with the patient or caregiver during the calendar month;~~ first 20 minutes
+ ▲	**98981**	~~Remote therapeutic monitoring treatment management services, physician or other qualified health care professional time in a calendar month requiring at least one interactive communication with the patient or caregiver during the calendar month;~~ each additional 20 minutes (List separately in addition to code for primary procedure)

75

Category III Codes

~~0042T~~	~~Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time~~
~~0266T~~	~~Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)~~
~~0267T~~	~~lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)~~
~~0268T~~	~~pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)~~
~~0269T~~	~~Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)~~
~~0270T~~	~~lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)~~
~~0271T~~	~~pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)~~

76

Category III Codes

~~**0272T**~~ ~~Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);~~

~~**0273T**~~ ~~with programming~~

▲ **0274T** Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral;, cervical or thoracic

~~**0275T**~~ ~~Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar~~

~~**0394T**~~ ~~High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed~~

77

Category III Codes

#● **0948T** Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation system with interim analysis, review, and report(s) by a physician or other qualified health care professional

#● **0949T** Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results

~~**0421T**~~ ~~Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)~~

#● **0950T** Ablation of benign prostate tissue, transrectal, with high intensity–focused ultrasound (HIFU), including ultrasound guidance

78

Category III Codes

~~0623T~~ ~~Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report~~

~~0624T~~ ~~data preparation and transmission~~

~~0625T~~ ~~computerized analysis of data from coronary computed tomographic angiography~~

~~0626T~~ ~~review of computerized analysis output to reconcile discordant data, interpretation and report~~

▲ **0598T** ~~Noncontact r~~Real-time fluorescence wound imaging with~~,~~ clinical darkness, to identify ~~for~~location of bacterial ~~presence, location~~wound pathogens~~,~~ ~~and load~~and measure wound size, per session; first anatomic site (eg, lower extremity, right leg)

+▲ **0599T** each additional anatomic site (eg, upper extremity, left leg) (List separately in addition to code for primary procedure)

79

Category III Codes

▲ **0600T** Ablation, irreversible electroporation; 1 or more tumors per organ, other than liver or prostate, including imaging guidance, when performed, percutaneous

~~0619T~~ ~~Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed~~

~~0631T~~ ~~Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity~~

~~0662T~~ ~~Scalp cooling, mechanical; initial measurement and calibration of cap~~

~~0663T~~ ~~placement of device, monitoring, and removal of device (List separately in addition to code for primary procedure)~~

~~0720T~~ ~~Percutaneous electrical nerve field stimulation, cranial nerves, without implantation~~

80

Category III Codes

#● **0988T** subcutaneous and subfascial

#● **0989T** subcutaneous and subfascial

● **0951T** Totally implantable active middle ear hearing implant; initial placement, including mastoidectomy, placement of and attachment to sound processor

● **0952T** revision or replacement, with mastoidectomy and replacement of sound processor

● **0953T** revision or replacement, without mastoidectomy and replacement of sound processor

● **0954T** replacement of sound processor only, with attachment to existing transducers

● **0955T** removal, including removal of sound processor and all implant components

● **0956T** Partial craniectomy, channel creation, and tunneling of electrode for sub-scalp implantation of an electrode array, receiver, and telemetry unit for continuous bilateral electroencephalography monitoring system, including imaging guidance

81

Category III Codes

● **0957T** Revision of sub-scalp implanted electrode array, receiver, and telemetry unit for electrode, when required, including imaging guidance

● **0958T** Removal of sub-scalp implanted electrode array, receiver, and telemetry unit for continuous bilateral electroencephalography monitoring system, including imaging guidance

● **0959T** Removal or replacement of magnet from coil assembly that is connected to continuous bilateral electroencephalography monitoring system, including imaging guidance

● **0960T** Replacement of sub-scalp implanted electrode array, receiver, and telemetry unit with tunneling of electrode for continuous bilateral electroencephalography monitoring system, including imaging guidance

+● **0961T** Shortwave infrared radiation imaging, surgical pathology specimen, to assist gross examination for lymph node localization in fibroadipose tissue, per specimen (List separately in addition to code for primary procedure)

82

Category III Codes

- **0962T** Assistive algorithmic analysis of acoustic and electrocardiogram recording for detection of cardiac dysfunction (eg, reduced ejection fraction, cardiac murmurs, atrial fibrillation), with review and interpretation by a physician or other qualified health care professional
- **0963T** Anoscopy with directed submucosal injection of bulking agent into anal canal
- **0964T** Impression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; single arch, without mandibular advancement mechanism
- **0965T** dual arch, with additional mandibular advancement, non-fixed hinge mechanism
- **0966T** dual arch, with additional mandibular advancement, fixed hinge mechanism
- **0967T** Transanal insertion of endoluminal temporary colorectal anastomosis protection device, including vacuum anchoring component and flexible sheath connected to external vacuum source and monitoring system

83

Category III Codes

- **0968T** Insertion or replacement of epicranial neurostimulator system, including electrode array and pulse generator, with connection to electrode array
- **0969T** Removal of epicranial neurostimulator system
- **0970T** Ablation, benign breast tumor (eg, fibroadenoma), percutaneous, laser, including imaging guidance when performed, each tumor
- **0971T** Ablation, malignant breast tumor(s), percutaneous, laser, including imaging guidance when performed, unilateral
- **0972T** Assistive algorithmic classification of burn healing (ie, healing or nonhealing) by noninvasive multispectral imaging, including system set-up and acquisition, selection, and transmission of images, with automated generation of report

84

Category III Codes

- **0973T** Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, trunk, arms, legs; first 100 sq cm
- **+ 0974T** each additional 100 sq cm (List separately in addition to code for primary procedure)
- **0975T** Selective enzymatic debridement, partial-thickness and/or full-thickness burn eschar, requiring anesthesia (ie, general anesthesia, moderate sedation), including patient monitoring, scalp, neck, hands, feet, and/or multiple digits; first 100 sq cm
- **+ 0976T** each additional 100 sq cm (List separately in addition to code for primary procedure)
- **0977T** Upper gastrointestinal blood detection, sensor capsule, with interpretation and report
- **0978T** Submucosal cryolysis therapy; soft palate, base of tongue, and lingual tonsil
- **0979T** soft palate only
- **0980T** base of tongue and lingual tonsil only

85

Category III Codes

- **0981T** Transcatheter implantation of wireless inferior vena cava sensor for long-term hemodynamic monitoring, including deployment of the sensor, radiological supervision and interpretation, right heart catheterization, and inferior vena cava venography, when performed
- **0982T** Remote monitoring of implantable inferior vena cava sensor, physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial set-up and patient education on use of equipment
- **0983T** Remote monitoring of an implanted inferior vena cava sensor for up to 30 days, including at least weekly downloads of inferior vena cava area recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional
- **+ 0984T** Intravascular imaging of extracranial cerebral vessels using optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention, including all associated radiological supervision, interpretation, and report; initial vessel (List separately in addition to code for primary procedure)
- **+ 0985T** each additional vessel (List separately in addition to code for primary procedure)

86

Category III Codes

+ • **0986T** Intravascular imaging of intracranial cerebral vessels using optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention, including all associated radiological supervision, interpretation, and report; initial vessel (List separately in addition to code for primary procedure)

+ • **0987T** each additional vessel (List separately in addition to code for primary procedure)

• **0990T** Transcervical instillation of biodegradable hydrogel materials, intrauterine

• **0991T** Cystourethroscopy, with low-energy lithotripsy and acoustically actuated microspheres, including imaging

• **0992T** Noninvasive assessment of cardiac risk derived from augmentative software analysis of perivascular fat without concurrent computed tomography (CT) scan of the heart, including patient-specific clinical factors, with interpretation and report by a physician or other qualified health care professional

87

Category III Codes

+ • **0993T** Noninvasive assessment of cardiac risk derived from augmentative software analysis of perivascular fat with concurrent computed tomography scan of the heart, including patient-specific clinical factors, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)

• **0994T** Endovascular delivery of aortic wall stabilization drug therapy through a sheath positioned within an abdominal aortic aneurysm, with aortic roadmapping, balloon occlusion, imaging guidance, and radiological supervision and interpretation; percutaneous

• **0995T** open

• **0996T** Insertion and scleral fixation of a capsular bag prosthesis containing an intraocular lens prosthesis, with vitrectomy, including removal of crystalline lens or dislocated intraocular lens prosthesis, when performed

• **0997T** Precuneus magnetic stimulation; treatment planning using magnetic resonance imaging-guided neuronavigation to determine optimal location, dose, and intensity for magnetic stimulation therapy, derived from evoked potentials from single pulses of electromagnetic energy recorded by 64-channel electroencephalogram, including automated data processing, transmission, analysis, generation of treatment parameters with review, interpretation, and report

88

Category III Codes

- **0998T** personalized treatment delivery of magnetic stimulation therapy to a prespecified target area derived from analysis of evoked potentials within the precuneus, utilizing magnetic resonance imaging-based neuronavigation, with management, per day
- **0999T** Autologous muscle cell therapy, harvesting of muscle progenitor cells, including ultrasound guidance, when performed
- **1000T** Autologous muscle cell therapy, administration of muscle progenitor cells into the urethral sphincter, including cystoscopy and post-void residual ultrasound, when performed
- **1001T** Autologous muscle cell therapy, injection of muscle progenitor cells into the external anal sphincter, including ultrasound guidance, when performed
- **1002T** Air displacement plethysmography, whole-body composition assessment, with interpretation and report
- **1003T** Arthroplasty, first carpometacarpal joint, with distal trapezial and proximal first metacarpal prosthetic replacement (eg, first carpometacarpal total joint)

89

Category III Codes

- **1004T** Electronic analysis of implanted sub-scalp continuous bilateral electroencephalography monitoring system (eg, contact group[s], gain, bandpass filters) by physician or other qualified health care professional; without programming
- **1005T** with programming, first 15 minutes face-to-face time with physician or other qualified health care professional
- **+ 1006T** with programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)
- **1007T** Electroencephalogram from implanted sub-scalp continuous bilateral electroencephalography monitoring system, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and report, up to 30 days of recording without video
- **1008T** Remote monitoring of sub-scalp implanted continuous bilateral electroencephalography monitoring system, device fitting, initial set-up, and patient education in wearing of system and use of equipment

90

Category III Codes

- **1009T** Remote monitoring of a sub-scalp implanted continuous bilateral electroencephalography monitoring system, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and report, up to 30 days of recording without video
- **1010T** Computerized ophthalmic analysis of monocular eye movements using retinal-based eye-tracking without spatial calibration, including fixation, microsaccades, drift, and horizontal saccades, when performed, unilateral or bilateral, with interpretation and report
- **1011T** Photobiomodulation (PBM) therapy of oral cavity, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device
- **1012T** Motorized ab interno trephination of sclera (sclerostomy), or trabecular meshwork (trabeculostomy), 1 or more, including injection of antifibrotic agents, when performed
- **1013T** Laparoscopy, surgical, implantation or replacement of lower esophageal sphincter neurostimulator electrode array and neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver, including cruroplasty and/or electronic analysis, when performed

91

Category III Codes

- **1014T** Laparoscopic revision or removal, lower esophageal sphincter neurostimulator electrodes
- **1015T** Revision or removal, lower esophageal sphincter neurostimulator pulse generator or receiver
- **1016T** Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of waveform, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements), lower esophageal sphincter neurostimulator pulse generator/transmitter; intraoperative, with programming
- **1017T** subsequent, without reprogramming
- **1018T** subsequent, with reprogramming
- **1019T** Lymphovenous bypass, including robotic assistance, when performed, per extremity

92

Category III Codes

- **1020T** Raman spectroscopy of 1 or more skin lesions, with probability score for malignant risk derived by algorithmic analysis of data from each lesion
- **1021T** Active thoracic irrigation (separate procedure)
- ✚ **1022T** Percutaneous tissue displacement, any method, including imaging guidance; intra-abdominal/pelvic structures (List separately in addition to code for primary procedure)
- ✚ **1023T** intrathoracic structures (List separately in addition to code for primary procedure)
- ✚ **1024T** soft tissue (List separately in addition to code for primary procedure)
- **1025T** Alternating electric fields dosimetry and delivery-simulation modeling, creation and selection of patient-specific array layouts, and placement verification

93